Search - sphingotec.com

81. sphingotec’s proprietary biomarker bio-ADM® detects residual congestion in patients with heart failure

Diagnostics company SphingoTec GmbH (sphingotec) today announced the publication of new study results in the European Journal of Heart Failure demonstrating that its proprietary endothelial function…

82. SphingoTec to Present Novel Acute Care Biomarkers and Point-of-Care Diagnostic Solutions at Medica 2019

SphingoTec GmbH (“sphingotec”) today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in…

83. Novel Data on sphingotec’s penKid® Kidney Function Assay to be Presented at 32nd ESICM Annual Congress 2019

SphingoTec GmbH (“sphingotec”) today announced that novel data on its sphingotest® penKid® assay for Proenkephalin, a unique and proprietary biomarker for real-time assessment of kidney function,…

84. Dipeptidyl Peptidase 3 (DPP3) cause of acute myocardial depression: sphingotec launches first IVD test for DPP3 on Nexus IB10 Point-of-Care platform

Diagnostics company SphingoTec GmbH (“sphingotec”, Hennigsdorf near Berlin, Germany) today launched IB10 sphingotest® DPP3, the first CE-IVD-marked point-of-care biomarker test able to quantify DPP3…

85. sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM)

Diagnostics company SphingoTec GmbH reports novel applications of bio-ADM® (bio-active adrenomedullin), the very first biomarker capable to diagnose the onset of septic shock, allowing physicians…

86. sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference on Advances in Critical Care Nephrology

German diagnostics company SphingoTec GmbH (Hennigsdorf) announced that leaders in critical care nephrology have confirmed clinical utility of the company’s glomerular filtration biomarker…

87. Endothelial disruption: Rapid translation from bench to bedside

bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency…

88. sphingotec raises €20 million from HBM and Wellington Partners

German diagnostics company SphingoTec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners.

89. sphingotec is adding an advanced POC testing platform to portfolio

German diagnostics company SphingoTec GmbH (Hennigsdorf) and Nexus Dx (San Diego) have combined their technology platforms to market sphingotec’s CE-marked acute biomarkers penKid® and bio-ADM® on…

90. Medical leaders support novel theragnostic approach to help patients with leaky blood vessels

Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more…